AdachiYKindzelskiiALCookinghamG. Aberrant neutrophil trafficking and metabolic oscillations in severe pyoderma gangrenosum. J Invest Dermatol1998;111:259–68.
2.
OkaMBerkingCNesbitM. Interleukin-8 overexpression is present in pyoderma gangrenosum ulcers and leads to ulcer formation in human skin xenografts. Lab Invest2000;80:595–604.
3.
WeenigRHDavisMDDahlPR. Skin ulcers misdiagnosed as pyoderma gangrenosum. N Engl J Med2002;347:1412–8.
4.
ReichrathJBensGBonowitzA. Treatment recommendations for pyoderma gangrenosum: An evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol2005;53:273–83.
5.
WollinaU. Clinical management of pyoderma gangrenosum. Am J Clin Dermatol2002;3:149–58.
6.
GrahamJAHansenKKRabinowitzLG. Pyoderma gangrenosum in infants and children. Pediatr Dermatol1994;11:10–7.
7.
BennettMLJacksonJMJorizzoJL. Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine (Baltimore)2000;79:37–46.
8.
SuWPDavisMDWeenigRH. Pyoderma gangrenosum: Clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol2004;43:790–800.
PowellFCSuWPDPerryHO. Pyoderma gangrenosum: Classification and management. J Am Acad Dermatol1996; 34:395–409.
11.
LindorNMArsenaultTMSolomonH. A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clin Proc1997;72:611–5.
12.
SuWPSchroeterALPerryHO. Histopathologic and immunopathologic study of pyoderma gangrenosum. J Cutan Pathol1986;13:323–30.
13.
BrooklynTNDunnillMGShettyA. Infliximab for the treatment of pyoderma gangrenosum: A randomised, double blind, placebo controlled trial. Gut2006;55:505–9.
14.
RegueiroMValentineJPlevyS. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol2003;98:1821–6.
15.
ArnottIDMcDonaldDWilliamsA. Clinical use of infliximab in Crohn's disease: The Edinburgh experience. Aliment Pharmacol Ther2002;15:1639–46.
16.
BatresLAMamulaPBaldassanoRN. Resolution of severe peristomal pyoderma gangrenosum with infliximab in a child with Crohn disease. J Pediatr Gastroenterol Nutr2002;34:558–60.
17.
BotrosNPickoverLDasKM. Image of the Month. Pyoderma gangrenosum caused by ulcerative colitis. Gastroenterology2000;118:654, 809.
18.
CoccoAAngelucciEViscidoA. Successful treatment with infliximab of refractory pyoderma gangrenosum in 2 patients with inflammatory bowel diseases. Inflamm Bowel Dis2007;13:1317–9.
19.
De la MorenaFMartinLGisbertJP. Refractory and infected pyoderma gangrenosum in a patient with ulcerative colitis: Response to infliximab. Inflamm Bowel Dis2007;14:509–10.
20.
ErmisFOzdilSAkyuzF. Pyoderma gangrenosum treated with infliximab in inactive ulcerative colitis. Inflamm Bowel Dis2008;14:1611–3.
21.
FernandezAVelascoAPrietoV. Response to infliximab in atypical pyoderma gangrenosum associated with ulcerative colitis. Am J Gastroenterol2008;103:2951–2.
22.
GrangeFDjilali-BouzinaFWeissAM. Corticosteroid-resistant pyoderma gangrenosum associated with Crohn's disease: Rapid cure with infliximab. Dermatology2002;205:278–80.
23.
HughesAPJacksonJMCallenJP. Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA2000;284:1546–8.
24.
KouklakisGMoschosJLeontiadisGI. Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report. Rom J Gastroenterol2005;14:401–3.
25.
KugathasanSMirandaANoctonJ. Dermatologic manifestations of Crohn disease in children: Response to infliximab. J Pediatr Gastroenterol Nutr2003;37:150–4.
26.
LjungTStaunMGroveO. Pyoderma gangrenosum associated with Crohn disease: Effect of TNF-alpha blockade with infliximab. Scand J Gastroenterol2002;37:1108–10.
27.
MimouniDAnhaltGJKoubaDJ. Infliximab for peristomal pyoderma gangrenosum. Br J Dermatol2003;148:813–6.
SapienzaMSCohenSDimaniroAJ. Treatment of pyoderma gangrenosum with infliximab in Crohn's disease. Dig Dis Sci2004;49:1454–7.
30.
TanMHGordonMLebwohlO. Improvement of pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol2001;137:930–3.
31.
TriantafillidisJKCheracakisPSklavainaM. Favorable response to infliximab treatment in a patient with active Crohn disease and pyoderma gangrenosum. Scand J Gastroenterol2002;37:863–5.
32.
ZaccagnaABertoneAPuiattiP. Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of pyoderma gangrenosum associated with Crohn's disease. Eur J Dermatol2003;13:258–60.
33.
PomerantzRGHusniMEModyE. Adalimumab for treatment of pyoderma gangrenosum. Br J Dermatol2007;157:1274–5.
34.
HeffernanMPAnadkatMJSmithDI. Adalimumab treatment for pyoderma gangrenosum. Arch Dermatol2007;143:306–8.
35.
CharlesCALeonABantaMR. Etanercept for the treatment of refractory pyoderma gangrenosum: A brief series. Int J Dermatol2007;46:1095–9.
36.
DislaEQuayamBCuppariGG. Successful use of etanercept in a patient with pyoderma gangrenosum complicating rheumatoid arthritis. J Clin Rheumatol2004;10:50–2.
37.
KeaneFMMacFarlaneCSMunnSE. Pyoderma gangrenosum and hepatitis C virus infection. Br J Dermatol1998;139:924–5.
38.
SmithJBShenefeltPDSotoO. Pyoderma gangrenosum in a patient with cryoglobulinemia and hepatitis C successfully treated with interferon alfa. J Am Acad Dermatol1996;34:901–3.
39.
DuffillMB. Cyclosporine, azathioprine and local therapy for pyoderma gangrenosum. Australas J Dermatol1994;35:15–8.
40.
KoCBWaltonSWyattEH. Pyoderma gangrenosum: Associations revisited. Int J Dermatol1992;31:574–7.
41.
PeacheyRDG. Pyoderma gangrenosum of scalp. Br J Dermatol1974;90:106–8.
42.
LyonCCStapletonMSmithAJ. Topical tacrolimus in the management of peristomal pyoderma gangrenosum. J Dermatolog Treat2001;12:13–7.
43.
ChowRKHoVC. Treatment of pyoderma gangrenosum. J Am Acad Dermatol1996;34:1047–60.
44.
GardnerLWAckerDW. Triamcinolone and pyoderma gangrenosum. Arch Dermatol1972;106:599–600.
45.
GoldsteinFKrainRThorntonJJ. Intralesional steroid therapy of pyoderma gangrenosum. J Clin Gastroenterol1985;7:499–501.
46.
JenningsJL. Pyoderma gangrenosum: Successful treatment with intralesional steroids. J Am Acad Dermatol1983;9:575–80.
47.
MoschellaSL. Pyoderma gangrenosum: A patient successfully treated with intralesional injections of steroid. Arch Dermatol1967;95:121–3.
48.
JollesSNiclasseSBensonE. Combination oral and topical tacrolimus in therapy-resistant pyoderma gangrenosum. Br J Dermatol1999;140:564–5.
49.
KimbleRMTicklerAKNichollsVS. Successful topical tacrolimus (FK506) therapy in a child with pyoderma gangrenosum. J Pediatr Gastroenterol Nutr2002;34:555–7.
50.
KontosAPKerrHAFivensonDP. An open-label study of topical tacrolimus ointment 0.1% under occlusion for the treatment of pyoderma gangrenosum. Int J Dermatol2006;45:1383–5.
51.
ReichKVenteCNeumannC. Topical tacrolimus for pyoderma gangrenosum. Br J Dermatol1998;139:755–7.
52.
Richter-HintzDSchuppeHCHomeyB. Topical tacrolimus (FK506) is effective in the treatment of pyoderma gangrenosum. J Am Acad Dermatol2000;42:304–5.
53.
SchuppeHCHomeyBAssmannT. Topical tacrolimus for pyoderma gangrenosum. Lancet1998;351:832.
54.
VidalDAlomarA. Successful treatment of peristomal pyoderma gangrenosum using topical tacrolimus. Br J Dermatol2004;150:387–8.
55.
BelliniVSimonettiSLisiP. Successful treatment of severe pyoderma gangrenosum with pimecrolimus cream 1%. J Eur Acad Venereol Dermatol2008;1:113–5.
56.
HoltPJDaviesMGSaundersKC. Pyoderma gangrenosum: Clinical and laboratory findings in 15 patients with special reference to polyarthritis. Medicine (Baltimore)1980;59:114–33.
57.
MlikaRBRiahiIFennicheS. Pyoderma gangrenosum: A report of 21 cases. Int J Dermatol2002;41:65–8.
58.
SheldonDGSawchukLLKozarekRA. Twenty cases of peristomal pyoderma gangrenosum: Diagnostic implications and management. Arch Surg2000; 135:564–9.
59.
VidalDPuigLGilaberteM. Review of 26 cases of classical pyoderma gangrenosum: Clinical and therapeutic features. J Dermatolog Treat2004;15:146–52.
60.
JohnsonRBLazarusGS. Pulse therapy. Therapeutic efficacy in the treatment of pyoderma gangrenosum. Arch Dermatol1982;18:57–64.
61.
PrystowskyJHKahnSNLazarusGS. Present status of pyoderma gangrenosum: Review of 21 cases. Arch Dermatol1989;125:57–64.
62.
ElgartGStoverPLarsenK. Treatment of pyoderma gangrenosum with cyclosporine: Results in seven patients. J Am Acad Dermatol1991;24:83–6.
63.
MatisWLEllisCNGriffithsCEM. Treatment of pyoderma gangrenosum with cyclosporine. Arch Dermatol1992;128:1060–4.
64.
O'DonnellBPowellFC. Cyclosporin treatment of pyoderma gangrenosum. J Am Acad Dermatol1991; 24:141–3.
65.
GriffithsCEKatsambasADijkmansBA. Update on the use of cyclosporin in immune-mediated dermatoses. Br J Dermatol2006;155Suppl 2:1–16.
Berth-JonesJTanSVGraham-BrownRAC. The successful use of minocycline in pyoderma gangrenosum—a report of seven cases and review of the literature. J Dermatolog Treat1989;1:23–5.
68.
DaviesMGPiperS. Pyoderma gangrenosum: Successful treatment with minocycline. Clin Exp Dermatol1981;6:219–23.
69.
LynchWSBergfeldWF. Pyoderma gangrenosum responsive to minocycline hydrochloride. Cutis1978;21:535–8.
70.
BrownRELayLGrahamD. Bilateral pyoderma gangrenosum of the hand: Treatment with dapsone. J Hand Surg Br1993;18:119–21.
71.
GalunEFlugelmanMYRachmilewitzD. Pyoderma gangrenosum complicating ulcerative colitis: Successful treatment with methylprednisolone pulse therapy and dapsone. Am J Gastroenterol1986;81:988–9.
72.
MirandaMF. Pyoderma gangrenosum with sulfasalazine and dapsone. Indian J Dermatol Venereol Leprol2002;68:160–1.
73.
TeaslerLAFosterCSBaltatzisS. Sclerokeratitis and facial skin lesions: A case report of pyoderma gangrenosum and its response to dapsone therapy. Cornea2007;26:215–9.
74.
TeitelAD. Treatment of pyoderma gangrenosum with methotrexate. Cutis1996;57:326–8.
75.
BatraAKLeveyJMTristerJ. Pyoderma gangrenosum in a patient with collagenous colitis. J Am Acad Dermatol2003;49:S277–9.
76.
DanielsNHCallenJP. Mycophenolate mofetil is an effective treatment for peristomal pyoderma gangrenosum. Arch Dermatol2004;140:1427–9.
77.
GilmourEStewartDG. Severe recalcitrant pyoderma gangrenosum responding to a combination of mycophenolate mofetil with cyclosporin and complicated by a mononeuritis. Br J Dermatol2001;144:397–400.
78.
HohenleutnerUMohrVDMichelS. Mycophenolate mofetil and cyclosporine treatment for recalcitrant pyoderma gangrenosum. Lancet1997;350:1748.
79.
NousariHCLynchWAnhaltGJ. The effectiveness of mycophenolate mofetil in refractory pyoderma gangrenosum. Arch Dermatol1998;134:1509–11.
80.
WollinaUKaramfilovT. Treatment of ralcitrant ulcers in pyoderma gangrenosum with mycophenolate mofetil and autologous keratinocyte transplantation on a hyaluronic acid matrix. J Eur Acad Dermatol Venereol2000; 14:187–90.
81.
CrawfordSEShermanRFavaraB. Pyoderma gangrenosum with response to cyclophosphamide therapy. J Pediatr1967;71:255–8.
82.
EnglishJSCFentonDABarthJ. Pyoderma gangrenosum and leucocytoclastic vasculitis in association with rheumatoid arthritis: A report of two cases. Clin Exp Dermatol1984;9:270–6.
83.
NewellLMMalkinsonFD. Pyoderma gangrenosum: Response to cyclophosphamide therapy. Arch Dermatol1983;119:495–7.
84.
Reynoso-von DratelnCPerla-NavarroAVGamez-NavaJI. Intravenous cyclophosphamide in pyoderma gangrenosum: An open trial. J Rheumatol1997;24:689–93.
85.
Zonana-NacachAJimenez-BalderasFJMartinez-OstunaP. Intravenous cyclophosphamide pulses in the treatment of pyoderma gangrenosum associated with rheumatoid arthritis: Report of 2 cases and review of the literature. J Rheumatol1994;21:1352–6.
86.
BuckleyCSarkanyIBayoumAHM. Pyoderma gangrenosum with severe pharyngeal ulceration. J R Soc Med1990;83:590–1.
87.
HeckerMSLebwohlMG. Recalcitrant pyoderma gangrenosum: Treatment with thalidomide. J Am Acad Dermatol1998;38:490–1.
88.
MunroCSCoxNH. Pyoderma gangrenosum associated with Behcet's syndrome—response to thalidomide. Clin Exp Dermatol1988;13:408–10.
89.
RustinMHGilkesJJRobinsonTW. Pyoderma gangrenosum associated with Behcet's disease: Treatment with thalidomide. J Am Acad Dermatol1990;23:941–4.
90.
VenenciePYSauratJ-H. Pyoderma gangrenosum in a child. Treatment with thalidomide. Ann Pediatr (Paris)1982;29:67–9.
91.
KaminskaRIkaheimoRHollmenA. Plasmapheresis and cyclophosphamide as successful treatments for pyoderma gangrenosum. Clin Exp Dermatol1999;24:81–5.
92.
KanekuraTKawaharaKMaruyamaI. Treatment of pyoderma gangrenosum with granulocyte and monocyte adsorption apheresis. Ther Apher Dial2005;9:292–6.
93.
OkumaKMitsuishiKHasegawaT. A case report of steroid and immunosuppressant-resistant pyoderma gangrenosum successfully treated by granulocytapheresis. Ther Apher Dial2007;11:387–90.
94.
SeishimaMMizutaniYShibuyaY. Efficacy of granulocyte and monocyte adsorption apheresis for three cases of refractory pyoderma gangrenosum. Ther Apher Dial2007;11:177–82.
95.
DirschkaTKastnerUBehrensS. Successful treatment of pyoderma gangrenosum with intravenous human immunoglobulin. J Am Acad Dermatol1998;39:789–90.
96.
GuptaAKShearNHSauderDN. Efficacy of human immune globulin in pyoderma gangrenosum. J Am Acad Dermatol1995;32:140–2.
